EUDA trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EUDA achieves its forward estimates and maintains a stable P/E multiple of 131.7x. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, EUDA Health Holdings Limited (EUDA) has a Wall Street consensus price target of N/A, based on estimates from 1 covering analysts. The company has a market capitalization of $29M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EUDA trades at a trailing P/E of -10.6x and forward P/E of 131.7x. Analysts expect EPS to grow -16.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ACMRACM Research, Inc. | $7.3B | $109.87 | $100.00 | -9.0% | Buy | 55.2x | 10 |
HIMSHims & Hers Health, Inc. | $7.8B | $35.47 | $28.08 | -20.8% | Hold | — | 20 |
TALKTalkspace, Inc. | $873M | $5.21 | $5.25 | +0.8% | Hold | 38.6x | 10 |
OPRXOptimizeRx Corporation | $93M | $4.98 | $17.00 | +241.4% | Buy | 5.3x | 15 |
WELLWelltower Inc. | $144.8B | $206.65 | $237.80 | +15.1% | Buy | 71.3x | 34 |
TDOCTeladoc Health, Inc. | $1.5B | $8.07 | $7.40 | -8.3% | Hold | — | 42 |
AMWLAmerican Well Corporation | $141M | $8.43 | $6.33 | -24.9% | Hold | — | 15 |
DOCSDoximity, Inc. | $3.8B | $20.46 | $29.47 | +44.0% | Hold | 14.3x | 23 |
GDRXGoodRx Holdings, Inc. | $922M | $2.66 | $3.08 | +15.8% | Hold | 8.6x | 24 |
VEEVVeeva Systems Inc. | $24.9B | $153.30 | $235.38 | +53.5% | Buy | 16.9x | 43 |
Quick answers to the most common questions about buying EUDA stock.
The consensus price target for EUDA is $N/A, close to the current price of $15.8 (N/A% implied move). Based on 1 analyst estimates, the stock appears fairly valued near current levels.
EUDA has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
At a forward P/E of 131.6667x, EUDA trades at a premium valuation. The consensus price target of $N/A (N/A% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $N/A for EUDA, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
EUDA is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EUDA stock forecast based on 1 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
EUDA trades at a forward P/E ratio of 131.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
EUDA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EUDA analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.